Stunning Progress Achieved in Lung Cancer Treatment Over the Last Decade

Liquid Biopsy’s Role in Marker Identification: An Interview With Dr. Martin Filipits

Artificial Intelligence in Lung Cancer: Opening New Avenues for Detection, Diagnosis, and Prognostication

Grappling with Coronavirus (SARS-CoV-2)

Increasing the Role of Local Consolidation in Oncogenic-Driven Advanced NSCLC

Treating Patients with MET Alterations: A Q&A with Dr. Ravi Salgia

TRK Inhibition in TRK Fusion–Positive Lung Cancers

Lung Cancer Surveillance After Definitive Curative-Intent Therapy: A Q&A With Dr. Edgardo S. Santos Castillero

CheckMate 568: Efficacy and Biomarker Analysis for Nivolumab and Ipilimumab in NSCLC

Smoking Ban in Austria Passed After Years of Political Wrangling

New FDA Commissioner Confirmed

Novel Insights on ctDNA Dynamics During Targeted Therapy and Immune Checkpoint Blockage in NSCLC